Mendus
0,45 SEK -5,06%17 investorer følger denne virksomhed
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
IMMU
Daglig lav / høj pris
0,436 / 0,474
SEK
Markedsværdi
388,42 mio. SEK
Aktieomsætning
870,56 t SEK
Volumen
1,9 mio.
Seneste videoer
Finanskalender
Generalforsamling
17.05.2024
Delårsrapport
17.05.2024
Delårsrapport
23.08.2024
Delårsrapport
08.11.2024
Årsrapport
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Adrianus Van Herk | 34,6 % | 34,6 % |
Thomas Eldered | 21,7 % | 21,7 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Mendus to present NK cell program progress at the Innate Killer Summit
Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools